Trial Profile

Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs InCVAX N dihydro galacto chitosan (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Soft tissue sarcoma
Focus Adverse reactions
Acronyms INJECTABL-1
Sponsors Immunophotonics

31 Jul 2025 According to the Immunophotonics Media Release, company announced the completion of treatment of the last patient in this trial.
08 Jan 2025 Planned End Date changed from 1 May 2025 to 1 Feb 2025.
08 Jan 2025 Planned primary completion date changed from 1 May 2025 to 1 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com